Annual report pursuant to Section 13 and 15(d)

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)

v3.21.1
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]    
Net operating loss carryforward - Federal $ 1,410,046 $ 854,196
Net operating loss carryforward - State 437,618 265,106
Stock option expense 178,053 72,504
Depreciation 12,958 8,753
Purchased in-process R&D 2,405,997
Federal orphan drug credits 427,343 283,189
Start-up expenditures and amortization 1,171,162 800,681
Total non-current deferred tax assets 6,043,177 2,284,429
Valuation allowance for deferred tax assets (4,139,829) (1,165,126)
Total deferred tax assets 1,903,348 1,119,303
Intangible asset (2,433,959) (2,650,933)
Total non-current deferred tax liabilities (2,433,959) (2,650,933)
Total deferred tax asset (liability) $ (530,611) $ (1,531,630)